{"organizations": [], "uuid": "a423be425d00c39f8bff859f0aa4fa871b0cdfe0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/roche-results/roche-lifts-2018-revenue-outlook-as-new-drug-sales-accelerate-idUSFWN1S3001", "country": "US", "domain_rank": 408, "title": "Roche lifts 2018 revenue outlook as new drug sales accelerate", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.171, "site_type": "news", "published": "2018-04-26T13:15:00.000+03:00", "replies_count": 0, "uuid": "a423be425d00c39f8bff859f0aa4fa871b0cdfe0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/roche-results/roche-lifts-2018-revenue-outlook-as-new-drug-sales-accelerate-idUSFWN1S3001", "ord_in_thread": 0, "title": "Roche lifts 2018 revenue outlook as new drug sales accelerate", "locations": [], "entities": {"persons": [{"name": "roche", "sentiment": "none"}, {"name": "michael shields", "sentiment": "none"}, {"name": "john miller", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "roche", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, April 26 (Reuters) - Roche raised its 2018 sales outlook on Thursday after getting a lift in the first three months of the year from newer drugs including Ocrevus, its soon-to-be blockbuster multiple sclerosis medicine.\nRoche, the worldâ€™s biggest cancer drugs maker, now predicts low-single-digit sales growth, after previously warning revenue could be flat. First-quarter sales rose 6 percent at constant exchange rates to 13.6 billion Swiss francs ($13.84 billion), compared to the average 13.3 billion franc analyst estimate in a Reuters poll.\n$1 = 0.9826 Swiss francs Reporting by John Miller; Editing by Michael Shields\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T13:15:00.000+03:00", "crawled": "2018-04-27T17:13:16.056+03:00", "highlightTitle": ""}